T1Pr αMT1, the GPI-anchored designer TIMP-1 created in this study, is a potent MT1-MMP inhibitor with the potential of being further developed into an experimental therapeutic for renal carcinoma treatment. This evidence concerns the gene MMP14 and renal carcinoma.